R&D News | pharmaphorum

News

Mixed data from lung cancer trials on show at WCLC

Highlights of the WCLC show include new data for AstraZeneca's Tagrisso, Summit's ivonescimab, MSD/Daiichi's I-DXd, and BMS/Systimmune's iza-bren.

News

NRG raises £50m to start trials of Parkinson's, ALS drug

NRG Therapeutics' oversubscribed Series B will fund first-in-human trials of a drug targeting mitochondrial dysfunction in neurodegenerative diseases.

News

Servier bets $450m on Fragile X syndrome drug

Servier has pushed its emerging neurology pipeline into the clinical trials stage by licensing a drug for Fragile X syndrome from the UK's Kaerus.

News

FDA releases previously unseen CRLs in transparency push

The FDA's earlier decision to publish complete response letters was largely a repackaging of existing information, but now it has gone much further.

News

Treeline's $200m Series A extension, and other biofinancings

Recent biotech financings include a $200m round for Treeline, with Enveda, Wugen, CHARM Therapeutics, and MRM Health also in on the action.

News

Gilead, Amgen kick off facility investments in US

This week saw both Gilead Sciences and Amgen start to fulfil pledges to step up capital investments in new US facilities.

Mixed data from lung cancer trials on show at WCLC

NRG raises £50m to start trials of Parkinson's, ALS drug

Servier bets $450m on Fragile X syndrome drug

FDA releases previously unseen CRLs in transparency push

Treeline's $200m Series A extension, and other biofinancings

Gilead, Amgen kick off facility investments in US

CDC panel votes to scrap hepatitis B birth dose advice

How to meet your physicians where they are online

News

Editor's Picks